Randomized dose-ranging study of a budesonide metered-dose inhaler by using co-suspension delivery technology in asthma

• Published in: Allergy and asthma proceedings Vol. 39; no. 5; p. 350
• Main Authors: Miller, S David, Nyberg, Jack, Siddiqui, Shahid, Dorinsky, Paul, St Rose, Earl, Reisner, Colin
• Format: Journal Article
• Language: English
• Published: United States 23.09.2018
• Subjects: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - adverse effects; Asthma - diagnosis; Asthma - drug therapy; Budesonide - administration & dosage; Budesonide - adverse effects; Dose-Response Relationship, Drug; Female; Humans; Male; Metered Dose Inhalers; Middle Aged; Respiratory Function Tests; Treatment Outcome; Young Adult
• ISSN: 1539-6304
• DOI: 10.2500/aap.2018.39.4155

This is the first study of the inhaled corticosteroid, budesonide, delivered by metered-dose inhaler (BD MDI) using innovative co-suspension delivery technology in adults with asthma. To characterize the effects of BD delivered by MDI on lung function and safety. Randomized, double-blind, 4-week cross-over, placebo-controlled, phase IIb study of adults (18-65 years of age) with mild-to-moderate persistent asthma. The subjects received twice-daily BD MDI 320 μg, 160 μg, and placebo MDI, and either BD MDI 80 μg or 40 μg. The primary endpoint was change from baseline in morning trough forced expiratory volume in 1 second (FEV1) at the end of the treatment period (EOT). Secondary endpoints included change from baseline in morning and evening predose peak expiratory flow rate (PEFR), rescue medication use, and Asthma Control Questionnaire 5-question version (ACQ-5) score. Safety was also assessed. A total of 147 subjects were randomized. All doses of BD MDI improved morning trough FEV1 at EOT, and morning and evening predose PEFR in the last treatment week versus placebo (all p < 0.01), with improvements in trough FEV1 exceeding 100 mL for BD MDI 320 μg, and 160 μg only. Compared with placebo, all BD MDI doses reduced rescue medication use in the last week of treatment (p < 0.01) and improved ACQ-5 scores at EOT (all p < 0.01). All treatments were well tolerated. Analysis of the data demonstrated greater efficacy improvements for the higher doses of BD MDI (320 μg and 160 μg), with similar adverse event profiles compared with the lower doses. Hence, BD MDI 320 μg and 160 μg warrant further evaluation in subjects with persistent asthma.Clinical trial NCT02105012, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>.